Simplifying Scale-up Manufacturing of RNA-LNPs for Vaccine and Cell Therapy Applications

Delivering nucleic acids using lipid nanoparticles (LNPs) to target cells has tremendous potential to enable the development of new cell and gene therapies as well as vaccines. LNPs can be used to deliver nucleic acids of various sizes, including RNA molecules, to precise locations in cells to treat cancer and other conditions. As interest and innovation in LNP-based delivery continues to grow, scaling-up manufacturing while ensuring the stability and safety of the therapies and vaccines that are developed is critical to successfully moving more medicines into the clinic.

In this GEN webinar, our expert speaker, Ian Johnston, discusses a genomic medicine toolkit for developing RNA-LNP medicines. This includes the NanoAssemblr™ NxGen™ manufacturing platform for rapid development and scalable manufacture of RNA-LNPs from lab scale (ml) to GMP manufacturing (liters) and off-the-shelf reagents for producing RNA-LNPs optimized for primary cells. Our speaker will share data on scale-up and rapid manufacture of RNA-LNP vaccines from preclinical development into clinical manufacturing. He will also share proof-of-concept data to develop ex vivo CAR T cell and hematopoietic stem cell therapies where LNPs enable RNA delivery for transient expression of immunogens, gene editing nucleases and therapeutic proteins.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.